Larimar Therapeutics, Inc. · NASDAQ:LRMR
Larimar Therapeutics — Zafgen — Merger or Acquisition (February 2020)
24 slides from Larimar Therapeutics's merger presentation, Feb 5, 2020
Slide 1: Schedule 14A Information - Zafgen, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Stat
Slide 2: Schedule 14A consists of an investor presentation
(1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: This Schedule 14A consists of an investor presentation. Members of Zafgen, Inc. management will be participating in upcoming meetings with investors. The following presentation will be use
Slide 3: Zafgen and Chondrial Therapeutics Planned Definitive Merger
Zafgen and Chondrial Therapeutics Planned Definitive Merger February 2020
Slide 4: Additional Information About the Proposed Merger
Forward transaction intends Investors because obtained Boston, proposed directors of thethese be unlawful proposed address to Massachusetts the (when Looking with and about merger. file of SEC directors of executive the relevant they and solicitation Zafgen on This proposed free Statements above. Za
Slide 5: Forward-Looking Statements
Forward statements combined company’s any timing of to ability consummate market expenditures result results These and merger, communication. events, the various product in to timing and other in and the stockholders or place of Looking torevisions company’s the other location are failure the of obt
Slide 6: Definitive merger agreement announced December 2019
Definitive (IND multiple or Phase assets merger 1) or or multiple agreement late (pivotal value announced trial) streamsüInnovative December Thoroughscientific 2019 evaluation Criteria approach of strategic included: in analternatives üNear-term attractive field Unanimous milestones – both market de
Slide 7: About the proposed merger
About of Board theDirectors proposed(four merger from Post-transaction Chondrial / three ownership from Zafgen) ~60% President Chondrialand / ~40% ChiefZafgen Executive stockholders Officer will Anticipated be Dr. Carole 1H 2020 Ben-Maimon closing New 5 company will operate under new name, Larimar T
Slide 8: Compelling value-creation opportunity
Compelling value-creation opportunities Upcoming near-term opportunity valuePublicly creatingtraded, eventsclinical-stage expected Experienced biopharmaceutical leadershipcompany team Potential focusedtoon have rareimpact disease onStrong significant scientific and devastating approach and diseases
Slide 9: Chondrial Therapeutics Overview
Chondrial Therapeutics Overview 7
Slide 10: Introduction to Chondrial Therapeutics
Introduction clinical results exclusivity indevelopment several expected to Chondrial models ifforapproved potential ofTherapeutics FA, including and treatment patents Clinical-stage heart, of pending Friedreich’s brain around biotech and muscle ataxia efficacy withfunction, (FA) a novel biomarkers
Slide 11: Proprietary protein replacement platform
Proprietary relevant andprotein applicable replacement to a rangeplatform of cargos Peptide and rare technology disease indications with proven9 ability to design molecules using cell-penetrating peptides (CPPs) that enable intracellular delivery of bioactive cargos Highly
Slide 12: Friedreich's ataxia (FA)
Friedreich’s Progressive, with difficulty include early more death development indrastic usually walking ataxia irreversible, progression) (FA): caused due of advanced significant to systemic by impaired heart Significant limb disease disease medical ability ataxia that asymptomatic due to need ofte
Slide 13: CTI-1601: delivering frataxin to the mitochondria
CTI-1601 COOH 3: Mitochondrial Site– of Delivering MPP Targeting cleavage frataxin Sequence STEP to the 1:(MTS) mitochondria CTI-1601 and crosses CPPCTI-1601: complex cell membrane recombinant leave andinto cellfusion cytoplasm mitochondria protein andintended STEP then crosses 4: to Mature deliver
Slide 14: CTI-1601: proof of concept in multiple nonclinical studies
CTI-1601: patients mitochondria with Proof FA Safe Extended ofand concept wellsurvival tolerated achievedinin through a well-characterized multiple multiple speciesnonclinical 12nonclinical studies model Nonclinical of FA Prevents efficacy ataxic and gait PD data in another provides nonclinical proo
Slide 15: CTI-1601 extends survival in FXN-deficient mice
CTI-1601 üConfirms of Survival MCK-Cre Percent extends that FXN-KO CTI-1601 P=0.0001 survival Mice isin Days capable 166 FXN-deficient MCK days of(CTI-1601) delivering = Muscle KO Mice creatine sufficient vs 98.0 Initial kinase days amounts Proof (Vehicle) 13 ofofConcept FXN Survival tofor mitochond
Slide 16: CTI-1601 prevents neurological phenotype in mouse model
CTI-1601 mouse Measures Stance phenotype CTI-1601 length Prevents prevents Treated variability given mice behavioral neurological intraperitoneally survive Survival phenotype longer phenotype analysis than (IP) inGait in mice untreated three neuro parameters that times KO lack mice mouse per endogen
Slide 17: CTI-1601 effectively delivers hFXN to mitochondria
hFXN concentration dose-dependent CTI-1601 effectively manner within traffics aftermitochondria to administration mitochondria; increases ofdelivers CTI-1601; in ahFXN dose-dependent activity N o rplateaus m a lmanner i zate 30 dM ümg/kg Given i t o cand hsubcutaneously oisn equivalent d r i a l h F
Slide 18: CTI-1601 prevents left ventricle dilation
CTI-1601 with Systole CTI-1601 KO: prevents CTI-1601 ü CTI-1601-treated left KO: ventricle Vehicle (LV) mice Wildtype: dilation similar üVehicle Left to controls; ventricular 16 echocardiogram volume increases showsinsignificant systole in untreated differencesmice between by 8 weeks KO: Vehicle (af
Slide 19: CTI-1601 preserves left ventricle function
CTI-1601 preserves significant differences leftbetween ventricle KO: (LV) Vehicle function andüKO: LeftCTI-1601 Ventricular treated function micedrops LV Ejection significantly Fraction in untreated LV Fractional mice by Shortening week 8 üKO: CTI-1601-treated CTI-1601 KO:mice Vehicle are similar Wi
Slide 20: PK/PD study in cynomolgus monkey
PK/PD study increase “healthies” 4x levels orinmore healthy (2-3x following higher cynomolgus CTI-1601 than FRDA monkey administration patients (studyCSF PK-1601-08) For wascomparison, collected ü Treatment pre- FRDA andof post-dose; patients monkeys have measured with 10-20% CTI-1601 levels of leve
Slide 21: Human frataxin distributed into all tissues tested
Human frataxin Cardiac TOX-1601-01RatsBrain, PK-1601-08Cynomolgus Mitochondria found ütoCSF be Heart, Monkey distributed (Cerebrospinal Liver CSF,PHARM-1601-02Neuro into Skin,all Fluid) Buccal tissues ü Cells, Skeletal testedPlatelets following Muscle KO MiceBrain, 19 üCTI-1601 Skin ü Buccal Dorsal
Slide 22: CTI-1601: safe and well tolerated in multiple animal models
CTI-1601: injection food higherconsumption, doses sites Safe Systemic raised andbody well and Toxicity weight firm; tolerated increased Analysis or in organ multiple injection No weight significant animal Nosite systemic models pathology clinical No histopathological observations at systemic higher
Slide 23: CTI-1601: Phase 1 clinical program
CTI-1601: CTI-1601 for Track clinical Designation vs. Initiated program placebo 21 Phase (5inGMP adult 1 clinical batches) patients program Topline with Friedreich’s evaluating results from safety ataxia this and Changes Phase efficacy 1 clinical frominbaseline FA program patients inexpected frataxi
Slide 24: Zafgen and Chondrial
Zafgen tee Chondrial